KCT0006640已完成未知
16 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Neoagaro-oligosaccharides on decrease of body fat
Wonkwang University Oriental Medical Hospital, Jeonju0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •1) 23 kg/m²=BMI(Body mass index)=34.9 kg/m², PBF(Percent body fat) is over 25% as male, over 30% as female.
- •2) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions
排除标准
- •1) Participants who have a change of weight over 10% within 3 months prior to the screening examination
- •2) Participants who have an obesity surgery within 1 year
- •3) Participants with a history of medicine abuse
- •4) Participants who have participated in other clinical trials within 3 months prior to the screening examination
研究者
相似试验
招募中
不适用
A 16-week, randomized, double-blinded, placebo-controlled study of HT077 and HT048 to evaluate efficacy and safety on health subjects with overweightKCT0004271EUMED120
进行中（未招募）
不适用
A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.Parkinson's DiseaseEUCTR2004-000817-20-LVKyowa Hakko U.K. Limited405
进行中（未招募）
不适用
A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa TherapyParkinson's DiseaseEUCTR2004-000817-20-ITKYOWA HAKKO UK LTD405
进行中（未招募）
1 期
A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.Parkinson's DiseaseEUCTR2004-000817-20-GBKyowa Hakko U.K. Limited405
进行中（未招募）
不适用
A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (istradefylline) and that of Entacapone versus Placebo as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.Parkinson's DiseaseEUCTR2004-000817-20-ATKyowa Hakko U.K. Limited405